Compare Ascendis Pharma A/S (ASND) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs FuelCell Energy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while FuelCell Energy Inc trades at $20.64 (market cap $1.68B). The key difference: Ascendis Pharma A/S is far larger — about 10.6× FuelCell Energy Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FCEL | |
|---|---|---|
Market Cap | $17.74B | $1.68B |
Sector | Health | Industrials |
52-Week High | $277.18 | $36.01 |
52-Week Low | $163.32 | $3.92 |
Enterprise Value | $18.11B | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FuelCell Energy (FCEL) trades at $21.03, down 8.57% amid recent volatility from a $225 million stock offering. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company continues to report losses with a net income margin of -132.41% in 2025, though revenue grew to $158.16 million. Recent news highlights a strategic partnership with Siemens to scale clean power solutions for data centers, a key growth area representing 90% of its sales pipeline.
FCEL presents a high-risk, high-reward opportunity driven by AI data center demand and new partnerships, but persistent profitability challenges and shareholder dilution from recent financing pose significant risks. Analyst consensus is mixed with a $20.13 price target, suggesting cautious optimism amid ongoing operational losses and competitive pressures in the fuel cell sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
